PATENT CLAIM ANALYSIS

Application Number: 16209051
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-11
Patent Classification: ["424", "465000"]

Abstract:
An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

Claim (Index 19):
A method of treating pulmonary hypertension in a human subject comprising administering to the human subject a solid oral dosage form comprising: (a) an osmotically-active drug core comprising treprostinil or a pharmaceutically acceptable salt thereof; and (b) a semi-permeable membrane surrounding the osmotically-active drug core, wherein the semi-permeable membrane comprises at least one opening having a diameter from 100 \u03bcm to 800 \u03bcm to permit osmotic release of the treprostinil or its pharmaceutically acceptable salt from the osmotically-active drug core, wherein the administration provides a therapeutically effective plasma concentration of treprostinil in the human subject.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14881374', '15162829', '11412100', '10655725', '14261709']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7361430191297296
- 35 USC 102 Novelty (BERT): 0.5331747690910533
- Combined Prediction Score: 0.715846194125862
- Mean Citation Score: 297.56756600000006
- Max Citation Score: 371.39285
- Similarity Product: 353.64560505939124

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test